DRUG DISCOVERY TODAY

Scope & Guideline

Pioneering Insights in Pharmacology and Drug Development

Introduction

Delve into the academic richness of DRUG DISCOVERY TODAY with our guidelines, detailing its aims and scope. Our resource identifies emerging and trending topics paving the way for new academic progress. We also provide insights into declining or waning topics, helping you stay informed about changing research landscapes. Evaluate highly cited topics and recent publications within these guidelines to align your work with influential scholarly trends.
LanguageEnglish
ISSN1359-6446
PublisherELSEVIER SCI LTD
Support Open AccessNo
CountryUnited Kingdom
TypeJournal
Convergefrom 1996 to 2024
AbbreviationDRUG DISCOV TODAY / Drug Discov. Today
Frequency12 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
Address125 London Wall, London EC2Y 5AS, ENGLAND

Aims and Scopes

The journal 'Drug Discovery Today' focuses on the latest advancements in drug discovery and development, emphasizing innovative methodologies and interdisciplinary approaches in pharmaceutical research.
  1. Drug Discovery and Development Processes:
    The journal covers comprehensive aspects of drug discovery, including target identification, lead discovery, optimization, and preclinical and clinical development.
  2. Innovative Therapeutic Strategies:
    It highlights novel therapeutic approaches, including small molecules, biologics, and combination therapies aimed at addressing complex diseases.
  3. Technological Integration:
    The journal emphasizes the integration of advanced technologies such as artificial intelligence, machine learning, and nanotechnology in the drug discovery process.
  4. Regulatory Perspectives:
    It discusses the regulatory challenges and frameworks that impact drug development, ensuring compliance with evolving standards in the pharmaceutical industry.
  5. Emerging Therapeutic Targets and Modalities:
    The journal explores new molecular targets and therapeutic modalities, including gene and cell therapies, immunotherapies, and precision medicine.
  6. Interdisciplinary Collaboration:
    It promotes collaboration between academia and industry to foster innovation in drug discovery, emphasizing the importance of cross-disciplinary research.
The journal 'Drug Discovery Today' is currently experiencing a surge in interest in several trending and emerging themes, reflecting the evolving landscape of drug discovery.
  1. Artificial Intelligence in Drug Discovery:
    The application of AI and machine learning in drug discovery is rapidly growing, facilitating data analysis, predictive modeling, and innovative approaches to target identification.
  2. Nanotechnology and Nanomedicine:
    There is an increasing focus on nanotechnology applications in drug delivery systems, enhancing therapeutic efficacy and reducing side effects.
  3. Immunotherapies and Personalized Medicine:
    Research on immunotherapies, especially in oncology, and personalized medicine approaches is trending, reflecting the shift towards tailored therapeutic strategies.
  4. Gene and Cell Therapies:
    Emerging interest in gene and cell therapies is notable, with advancements in CRISPR technologies and vector design for targeted therapeutic applications.
  5. Multi-Target Strategies:
    The exploration of multi-target drugs and polypharmacology is gaining traction as researchers seek to address complex diseases with multifactorial approaches.
  6. Sustainable Drug Development:
    There is a growing emphasis on environmentally sustainable practices in drug development, including greener chemistry and biodegradable materials.

Declining or Waning

In recent years, certain themes within 'Drug Discovery Today' have seen a decline in prominence, reflecting shifts in scientific focus and emerging research priorities.
  1. Traditional Drug Repurposing:
    While drug repurposing remains a relevant strategy, the focus on traditional methods has waned as novel approaches to drug discovery gain traction.
  2. Conventional Small Molecule Approaches:
    There is a noticeable decline in papers exclusively focused on conventional small molecule drug design, with more emphasis now on biologics and combination therapies.
  3. Single-Target Drug Development:
    The exploration of single-target drugs is decreasing as the field shifts towards multi-target strategies and polypharmacology to enhance therapeutic efficacy.
  4. Efficacy Studies without Mechanistic Insights:
    There is a decline in studies that report efficacy without delving into the underlying mechanisms, as the scientific community increasingly values mechanistic understanding.
  5. Focus on Established Therapeutics:
    Research centered on established therapeutics is declining in favor of innovative and experimental approaches that address unmet medical needs.

Similar Journals

Annual Review of Pharmacology and Toxicology

Elevating insights in pharmacology and toxicology.
Publisher: ANNUAL REVIEWSISSN: 0362-1642Frequency: 1 issue/year

Annual Review of Pharmacology and Toxicology is a leading journal published by ANNUAL REVIEWS, renowned for its comprehensive and critical reviews of the fields of pharmacology and toxicology. With an esteemed history spanning from 1965 to the present and an impressive Q1 ranking in both categories, this journal stands at the forefront of scholarly communication in pharmacological sciences. Researchers are encouraged to submit cutting-edge studies that advance knowledge and innovation in drug development, safety assessments, and therapeutic practices. Although this journal does not currently offer Open Access options, it remains a vital resource for professionals and students who seek to stay updated with the latest high-impact research findings. The journal is indexed in Scopus, boasting remarkable rankings, including Rank #1 in Toxicology and Rank #4 in Pharmacology, reflecting its pivotal role in shaping the discourse in these dynamic fields.

MEDICINAL RESEARCH REVIEWS

Elevating Biomedical Knowledge through Rigorous Review
Publisher: WILEYISSN: 0198-6325Frequency: 6 issues/year

MEDICINAL RESEARCH REVIEWS, published by Wiley, is a leading journal in the fields of Drug Discovery, Molecular Medicine, and Pharmacology. With an impressive impact factor and esteemed standing in its category quartiles (Q1 in all three fields), this journal serves as a vital platform for the dissemination of cutting-edge research and reviews that drive innovation in therapeutic development and molecular health sciences. Since its inception in 1981, MEDICINAL RESEARCH REVIEWS has garnered a robust readership within the scientific community, underscored by its high rankings in Scopus – where it ranks #3 in Pharmacology and #2 in Drug Discovery, placing it within the top echelons of academic influence. Researchers, professionals, and students alike benefit from its rich content and comprehensive approaches to tackling complex medicinal challenges, making it an essential resource for those invested in advancing the frontiers of biomedical research.

Drug Target Insights

Advancing the Future of Pharmacology and Drug Discovery.
Publisher: ABOUTSCIENCE SRLISSN: 1177-3928Frequency: 1 issue/year

Drug Target Insights is a prestigious peer-reviewed journal published by ABOUTSCIENCE SRL, catering to the dynamic field of pharmacology and medicinal biochemistry. With an Open Access policy since 2006, the journal aims to promote the dissemination of cutting-edge research and innovations that target drug discovery and therapeutic developments. Based in Milan, Italy, it boasts a notable impact within its research community, achieving a Q3 classification in the categories of Clinical Biochemistry and Medical Pharmacology in 2023, alongside a robust performance in the Q2 category for Pharmacology, Toxicology, and Pharmaceutics. The journal serves as a vital platform for researchers, professionals, and students seeking to advance their understanding of drug delivery systems, therapeutic targets, and pharmacodynamics. With a commitment to enhancing global access to crucial research findings, Drug Target Insights stands out as an essential resource for those engaged in the ever-evolving landscape of pharmaceutical sciences.

Letters in Drug Design & Discovery

Pioneering Research for a Healthier Future
Publisher: BENTHAM SCIENCE PUBL LTDISSN: 1570-1808Frequency: 12 issues/year

Letters in Drug Design & Discovery is an esteemed journal dedicated to advancing the fields of Drug Discovery and Molecular Medicine. Published by Bentham Science Publishers, this journal offers a platform for the dissemination of innovative research and advanced methodologies, enhancing collaboration among researchers and professionals in pharmaceutical sciences. Despite its current Q4 ranking in Drug Discovery and Molecular Medicine and Q3 in Pharmaceutical Science for 2023, the journal is committed to improving its presence in the academic community by providing quality, peer-reviewed publications that cover various aspects of drug design and discovery, including novel therapeutic approaches and methodologies. With a focus on both foundational and cutting-edge research from around the globe, Letters in Drug Design & Discovery is pivotal for those seeking to stay abreast of developments in drug development and molecular research. Researchers are encouraged to submit their work, engage with the burgeoning field, and contribute to the ongoing dialogue driven by this journal, which spans the years from 2005 to 2024. While the journal does not currently offer open access, its contributions remain accessible to a wide range of academic and professional audiences.

CURRENT PHARMACEUTICAL DESIGN

Pioneering Insights in Pharmacology and Drug Development
Publisher: BENTHAM SCIENCE PUBL LTDISSN: 1381-6128Frequency: 46 issues/year

CURRENT PHARMACEUTICAL DESIGN is a leading journal in the fields of Drug Discovery and Pharmacology, published by Bentham Science Publishers Ltd in the dynamic United Arab Emirates. With an impressive historical span from 1995 to 2024, this journal serves as a vital platform for disseminating innovative research findings, breakthrough methodologies, and critical reviews that shape the future of pharmaceutical sciences. Ranked Q2 in both Drug Discovery and Pharmacology categories according to the 2023 metrics, it places itself within the top-tier percentile, catering to a diverse audience of researchers, industry professionals, and students. The journal’s commitment to high-quality research exploration is evidenced by its Scopus ranking, where it is positioned favorably within its category ranks. Although currently not Open Access, CURRENT PHARMACEUTICAL DESIGN remains an essential resource for those looking to stay at the forefront of pharmacological advancements and drug development strategies.

Future Medicinal Chemistry

Advancing the frontiers of drug discovery.
Publisher: Newlands Press LtdISSN: 1756-8919Frequency: 24 issues/year

Future Medicinal Chemistry is a premier journal dedicated to the rapidly evolving fields of drug discovery, pharmacology, and molecular medicine. Published by Newlands Press Ltd in the United Kingdom, this journal has garnered significant attention within the academic community, evidenced by its 2023 category rankings in Scopus, placing it in the Q2 quartile for Drug Discovery and the Q3 quartiles for both Molecular Medicine and Pharmacology. With an ISSN of 1756-8919 and an E-ISSN of 1756-8927, Future Medicinal Chemistry has been a cornerstone of scholarly discourse since its inception in 2009, continuously contributing to the advancement of knowledge and discussion in medicinal chemistry. The journal is committed to publishing high-quality, peer-reviewed research that addresses the challenges and innovations in drug development and therapeutic strategies, making it an essential resource for researchers, professionals, and students seeking to stay at the forefront of these critical fields. Engage with the latest findings and methodologies that shape the future of medicine by exploring the wealth of information offered within Future Medicinal Chemistry.

EXPERT OPINION ON THERAPEUTIC PATENTS

Exploring the Intersection of Pharmacology and Patent Law
Publisher: TAYLOR & FRANCIS LTDISSN: 1354-3776Frequency: 12 issues/year

EXPERT OPINION ON THERAPEUTIC PATENTS, published by Taylor & Francis Ltd, is a prestigious journal dedicated to the critical analysis and commentary on therapeutic patents, emphasizing their impact on drug discovery and development. With an improving reputation reflected in its 2023 Q1 rankings in Drug Discovery and Pharmacology, this journal stands out as a leading source in the fields of pharmacology and medicine, holding significant relevance with a Scopus ranking in the 90th percentile for its contributions in Drug Discovery and a robust position in Pharmacology. Launched in 1991, the journal consistently engages researchers and professionals seeking to stay at the forefront of innovations in therapeutic patents, thus driving advancements in the pharmaceutical landscape. Although it does not offer Open Access, its comprehensive scope and commitment to quality make it an essential resource for those looking to explore the intersection of intellectual property and pharmacological research.

CURRENT OPINION IN PHARMACOLOGY

Fostering Dialogue on Emerging Drug Therapies
Publisher: ELSEVIER SCI LTDISSN: 1471-4892Frequency: 6 issues/year

Current Opinion in Pharmacology, an esteemed journal published by Elsevier Science Ltd, encompasses the vital field of pharmacology and drug discovery. With a solid impact factor and recognized as a Q1 journal in both Drug Discovery and Pharmacology categories for 2023, it serves as a premier platform for researchers and professionals to share innovative insights, discuss emerging trends, and explore the complexities of drug development and therapeutic applications. Established in 2001 and running through 2024, this journal provides a critical overview of advances in the field, aiming to inform and inspire the next generation of pharmacological research. Despite lacking Open Access options, it maintains a high standard of scholarly excellence, ensuring that the content remains impactful and relevant to its readers. The journal is based in the Netherlands, representing a key contributor to the academic landscape in pharmacology.

PHARMACEUTICAL CHEMISTRY JOURNAL

Fostering Innovation in Drug Development and Safety.
Publisher: SPRINGERISSN: 0091-150XFrequency: 12 issues/year

Pharmaceutical Chemistry Journal is a pivotal publication in the field of pharmaceutical sciences, renowned for its in-depth articles and research findings. Published by Springer in the United States, this journal provides a crucial platform for researchers, students, and professionals dedicated to advancing drug discovery and pharmacology. With an ISSN of 0091-150X and an E-ISSN of 1573-9031, this journal has consistently aimed to promote scholarly communication and innovation within its scope since its inception in 1967. Despite its current Category Quartiles ranking of Q4 in both Drug Discovery and Pharmacology, the journal remains a valuable resource for disseminating new ideas and findings that contribute to the scientific community. Researchers benefit from the journal's commitment to high-quality peer-reviewed content, even in an environment where open access options are currently not available. As the field evolves, the Pharmaceutical Chemistry Journal continues to play an important role in shaping future advancements in drug development and safety.

ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Delivering Impactful Research for Alimentary Therapies
Publisher: WILEYISSN: 0269-2813Frequency: 24 issues/year

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, published by Wiley, is a premier scholarly journal in the fields of gastroenterology, hepatology, and pharmacology. With an impressive impact factor and ranking in the top quartile (Q1) of its classifications, the journal is recognized for its rigorous peer-reviewed research and comprehensive reviews, aiming to advance the understanding of therapeutic interventions in gastrointestinal and liver diseases. Since its inception in 1987, it has become an essential resource for researchers, healthcare professionals, and students alike, fostering scientific dialogue and innovation. With a Scopus rank placing it in the 97th percentile for pharmacology and 96th for gastroenterology, it is dedicated to publishing the most significant and impactful findings in the field. ALIMENTARY PHARMACOLOGY & THERAPEUTICS thus plays a vital role in shaping the future of medical treatments and interventions in gastrointestinal health.